Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

por Zugmaier, G, Topp, M S, Alekar, S, Viardot, A, Horst, H-A, Neumann, S, Stelljes, M, Bargou, R C, Goebeler, M, Wessiepe, D, Degenhard, E, Gökbuget, N, Klinger, M
Publicado 2014

P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE L...

por McMillan, A., Haioun, C., Sancho, J.-M., Viardot, A., Rodriguez Izquierdo, A., Donato Martin, E. M., García-Sancho, A. M., Sandoval-Sus, J., Tilly, H., Vandenberghe, E., Hirata, J., Choudhry, P., Chang, Y. M., Musick, L., Matasar, M.
Publicado 2022

Randomised clinical study: inulin short‐chain fatty acid esters for targeted delivery of short‐chain fatty acids to the human colon

por Polyviou, T., MacDougall, K., Chambers, E. S., Viardot, A., Psichas, A., Jawaid, S., Harris, H. C., Edwards, C. A., Simpson, L., Murphy, K. G., Zac‐Varghese, S. E. K., Blundell, J. E., Dhillo, W. S., Bloom, S. R., Frost, G. S., Preston, T., Tedford, M. C., Morrison, D. J.
Publicado 2016